Immunome IMNM Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$212.39M+27.5% | -$292.96M-174% | -$106.81M-189% | -$36.9M-49.3% | ||
| $2.47M+57.4% | $1.57M+243% | $457K+8.3% | $422K-44.1% | ||
| $25.69M+63.1% | $15.75M+153% | $6.22M+16.7% | $5.33M+54.6% | ||
| -$190.92M-72.3% | -$110.79M— | —— | -$28.69M-57.4% | ||
| $9.69M+35.0% | $7.17M+763% | $831K+235% | $248K+214% | ||
| —— | —— | $9.28M— | —— | ||
| $64.8M— | —— | -$30.48M-12,192% | -$248K-214% | ||
| $640.41M+166% | $240.53M+107% | $116.41M— | —— | ||
| —— | —— | $84.36M+392% | -$28.91M— | ||
| -$200.6M-70.1% | -$117.97M— | —— | -$28.94M-58.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Immunome's cash flow data come from?
- Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.